Lupin gets US FDA approval for sodium zirconium cyclosilicate
This story was originally published at 20:39 IST on 10 August 2026
Register to read our real-time news.Informist, Monday, Aug. 10, 2026
--Lupin gets US FDA approval for sodium zirconium cyclosilicate
MUMBAI – Lupin Ltd. has received the US Food and Drug Administration's approval for its abbreviated new drug application for sodium zirconium cyclosilicate. The approval is for an oral suspension, to be sold in 5 gram/packet and 10 gram/packet strengths, Lupin said in an exchange filing Monday.
The drug is a generic version of Lokelma, used to treat hyperkalemia in adults. The drug had estimated sales of $568 million in 12 months ended June, according to data from IQVIA.
For the June quarter, Lupin reported a consolidated net profit of INR 14.15 billion on revenues of INR 82.77 billion. Monday, shares of the company close 2.7% lower at INR 2,300 on the National Stock Exchange. End
Reported by Anshul Choudhary
Edited by Deepshikha Bhardwaj
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
